Hemab Therapeutics (COAG) Stock Price, News & Analysis

Company Overview

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor. The program is being developed initially for Glanzmann thrombasthenia, a rare inherited platelet disorder, with potential applications in other bleeding conditions.

Hemab conducts its operations in the United States and Denmark and is advancing its pipeline through clinical development and related research. As a development-stage biotechnology company, its products remain investigational and subject to clinical and regulatory review.

Key Stats

• Today's Range: $29.01 to $30.42
• 50-Day Range: $28.37 to $54.94
• 52-Week Range: $23.00 to $55.42
• Volume: 224,941 shs
• Average Volume: 642,318 shs
• Market Capitalization: $1.40 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $54.71
• Consensus Rating: Moderate Buy

Hemab Therapeutics Stock Analysis - MarketRank™

Hemab Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 390th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Hemab Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Hemab Therapeutics has a consensus price target of $54.71, representing about 82.7% upside from its current price of $29.94.

Amount of Analyst Coverage

Hemab Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Hemab Therapeutics are expected to grow in the coming year, from ($3.09) to ($2.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hemab Therapeutics is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hemab Therapeutics is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.26% of the float of Hemab Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Hemab Therapeutics has a short interest ratio ("days to cover") of 4.18.

Change versus previous month

Short interest in Hemab Therapeutics has recently increased by 28.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hemab Therapeutics does not currently pay a dividend.

Dividend Growth

Hemab Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.03

News Sentiment

Hemab Therapeutics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Hemab Therapeutics this week, compared to 3 articles on an average week.

Search Interest

7 people have searched for COAG on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hemab Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Hemab Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:COAG
• CIK: 2114044
• Web: www.hemab.com
• Phone: (452) 138-7627
• Fax: N/A
• Employees: 59
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Hemab Therapeutics: $54.71
• High Price Target: $70.00
• Low Price Target: $36.00
• Potential Upside/Downside: +82.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 35.85
• Quick Ratio: 35.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 46,710,000
• Free Float: N/A
• Market Cap: $1.40 billion
• Optionable: N/A
• Beta: N/A